Joop de Langen
Antoni van Leeuwenhoek · The Netherlands Cancer Institute-Antoni van Leeuwenhoek
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joop de Langen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06222489 · Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CTThe Netherlands Cancer Institute · recruiting · Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation · principal investigator
- N/ANCT03564197 · 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLCThe Netherlands Cancer Institute · completed · NSCLC Stage IV · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.